Associated Papers
Acute myeloid leukemia with t(8;21) translocation: Molecular pathogenesis, potential therapeutics and future directions.
Han Yu P et al.
Biochemical Pharmacology, 2025
Mutation in the Unrearranged PML Allele Confers Resistance to Arsenic Trioxide in Acute Promyelocytic Leukemia.
Yu PH et al.
Research (washington, D.c.), 2025
A Sole p.G391E Mutation in PML::RARA Identified in Relapsed Acute Promyelocytic Leukemia
Su Z et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology, 2024
Mutations at proximal cysteine residues in PML impair ATO binding by destabilizing the RBCC domain.
Dubey S et al.
The Febs Journal, 2024
Phase separation is required for PML nuclear body biogenesis and function.
Wu W et al.
Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 2023
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
34630336 (PubMed )
Supplement: Table_1.xlsx › Tab2
Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse.
Iaccarino L et al.
American Journal of Hematology, 2019
Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia.
Hattori H et al.
Plos One, 2018
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.
Madan V et al.
Leukemia, 2016
Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.
Iaccarino L et al.
British Journal of Haematology, 2016
Varying responses of PML-RARA with different genetic mutations to arsenic trioxide.
Liu J et al.
Blood, 2016
p53 as an Effector or Inhibitor of Therapy Response.
Ablain J et al.
Cold Spring Harbor Perspectives in Medicine, 2015
Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
Lou Y et al.
Annals of Hematology, 2015
Secondary mutations as mediators of resistance to targeted therapy in leukemia.
Daver N et al.
Blood, 2015
Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.
Goto E et al.
Blood, 2011
Select a paper to view details